Combination therapy of local administration of OK-432 and radiation for esophageal cancer

Mukai, Minoru; Morita, Shinroku; Tsunemoto, H

doi:10.1016/0360-3016(92)90806-s

Cited by 13 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of MnSOD in the anti-tumor activity of OK432 is unknown. Howevcr, local administration of OK432 has been shown to enhance the effects of irradiation on cancer in vivo (Mukai et a/., 1992). Increased activity of MnSOD may protect granulocytes from superoxide radicals generated following irradiation, and these granulocytes may also work cytostatically.…”

Section: Akashi Etalmentioning

confidence: 99%

Anti-cancer agent OK432 induces manganese superoxide dismutase in human granulocytes

Akashi¹,

Takagi²,

Hachiya³

1996

Int. J. Cancer

View full text Add to dashboard Cite

Manganese superoxide dismutase (MnSOD) is a mitochondrial enzyme involved in scavenging O2-. OK432, a Streptococcal preparation, has anti-tumor activity and is also known to be a biological-response modifier. In this study, we have examined the regulation of MnSOD gene by OK432 in human granulocytes. Granulocytes had a low activity of MnSOD; OK432 increased MnSOD mRNA levels in a dose-dependent manner and its activity in granulocytes. OK432 also induced the MnSOD mRNA in HL60 promyelocytes, while not affecting the levels of MnSOD mRNA in human fibroblasts. Pre-treatment with either actinomycin D or cycloheximide inhibited the induction of MnSOD mRNA by OK432. OK432 increased the levels of interleukin-1 (IL-1) and tumor-necrosis-factor-alpha (TNFalpha) mRNA in granulocytes. Furthermore, the induction of MnSOD mRNA by OK432 was blocked by anti-IL-1 antibody but not by anti-TNF antibody. These results suggest that the induction of MnSOD mRNA by OK432 is regulated at the transcriptional level, and OK432 induces MnSOD mRNA, at least in part, through production of IL-1 in granulocytes.

show abstract

Section: Akashi Etalmentioning

confidence: 99%

Anti-cancer agent OK432 induces manganese superoxide dismutase in human granulocytes

Akashi¹,

Takagi²,

Hachiya³

1996

Int. J. Cancer

View full text Add to dashboard Cite

show abstract

“…7 We observed the improvement of the dyspnea a week after the injection of O K -432. This patient has been in good health without a sign of recurrence for more than 7 years.…”

Section: Discussionmentioning

confidence: 89%

Multidisciplinary treatment with OK-432 for tracheal or bronchial invasion by post-surgical esophageal cancer recurrences

Mukai¹,

Morita²,

Tsujii³

1996

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

Three patients with recurrent tumors invading the trachea or main bronchus after esophageal cancer surgery, underwent a multidisciplinary treatment using radiation and local administration of OK-432 with or without chemotherapy. Three patients were irradiated at a daily dose of 1.8 Gy, 5 fractions per week. The total dose of radiation ranged from 52.2 to 64.8 Gy. A dose of 1 mg or 0.5 mg of OK-432, dissolved in 3 mL of 0.5% xylocaine was administered submucosal[y at proximal sites of the tumor via a bronchofiberscope. Two of the patients also received a second injection of OK-432 2 weeks after the first dose. A complete response was obtained in 2 of the patients and a partial response occurred in the remaining patient. The patients with a complete response have been in good condition without any sign of recurrence for more than 2 and 6 years, respectively. Dyspnea was effectively cured in all 3 patients.

show abstract

“…The i.c. or intralesional injection of OK-432 is reported to be effective even when administered alone (Torisu et al, 1983;Fukuma et al, 1986;Fujita, 1987); however, intralesional injection of OK-432 also seems to be beneficial in conjunction with other adjuvant therapies, including radiotherapy (Mukai et al, 1995). This suggests that the effects of i.c.…”

mentioning

confidence: 71%

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion

et al. 1999

View full text Add to dashboard Cite

The current prospective randomized study was designed to compare the effects of intracavitary (i.c.) chemotherapy vs immunotherapy vs immunochemotherapy for malignant effusion. Between 1992 and 1995, a total of 42 patients with malignant effusion were registered, and 41 patients were eligible for statistical analysis. The primary diseases of the eligible patients included 27 gastric, four colorectal, four pancreatic, three lung, two liver and one oesophageal cancers. The patients with malignant effusion were randomly assigned into one of three i.c. therapeutic regimens: chemotherapy alone with weekly injection of anticancer agents (ACAs: cisplatin, mitomycin-C, adriamycin, etc.) (Group A, n = 13); immunotherapy alone with weekly injection of streptococcal preparation OK-432 (Group B, n = 14); or immunochemotherapy with ACAs and OK-432 (Group C, n = 14). The response of the effusion, patient survival and the kinetics of cytokines in the effusion were compared. There were no differences in the patients' backgrounds. The side-effects of the regimens included pain, anorexia, fever, leucopenia and anaemia and there were no differences in their incidence among the three groups. One patient died after cisplatin (CDDP) administration in Group A. Cytologic examination revealed that tumour cells in the effusion disappeared in 23% of Group A cases, 36% of Group B cases and 36% of Group C cases. The malignant effusion did not disappear in any of the Group A cases; however, the effusion disappeared in 29% of Group B cases and 43% of Group C cases ( P = 0.03, Group A vs Group C). Furthermore, the 50% survival period was 1.6 months for Group A, 2.4 months for Group B and 3.5 months for Group C. The 6-month survival rate was 7% for Group A, 6% for Group B and 34% for Group C, and the 1-year survival rate was 0%, 0% and 17% respectively ( P = 0.048, Group A vs Group C by the log-rank test). The analysis of the cytokine kinetics revealed a prominent increase in the level of interleukin-6 in the effusion in Group C. These results suggest that i.c. immunochemotherapy with OK-432 and ACAs may be more beneficial than i.c. chemotherapy alone or immunotherapy alone. © 1999 Cancer Research Campaign

show abstract

Combination therapy of local administration of OK-432 and radiation for esophageal cancer

Cited by 13 publications

References 4 publications

Anti-cancer agent OK432 induces manganese superoxide dismutase in human granulocytes

Anti-cancer agent OK432 induces manganese superoxide dismutase in human granulocytes

Multidisciplinary treatment with OK-432 for tracheal or bronchial invasion by post-surgical esophageal cancer recurrences

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion

Contact Info

Product

Resources

About